Engineering functional BMP-2 expressing teratoma-derived fibroblasts for enhancing osteogenesis

Area of Science:

• Biomaterials Science
• Regenerative Medicine
• Gene Therapy

Background:

• Bone morphogenetic protein 2 (BMP-2) is crucial for bone formation but clinical applications face challenges.
• Existing osteo-inductive scaffolds have shown limited success rates in bone regeneration.
• Genetic engineering offers potential for enhanced therapeutic efficacy and safety.

Purpose of the Study:

• To develop a novel gene-modified cell therapy for enhanced bone regeneration.
• To investigate the synergistic effects of BMP-2 and HSV-tk genes in osteogenesis.
• To assess the safety and efficacy of the engineered cells in preclinical models.

Main Methods:

• Teratoma-derived fibroblast (TDF) cells were genetically modified to co-express BMP-2 and HSV-tk.
• In vitro osteogenesis was evaluated by measuring alkaline phosphatase (ALP) activity and osteogenic gene expression.
• In vivo bone formation was assessed in critical-size calvarial and femoral defect models.
• Ganciclovir (GCV) was used to induce apoptosis in HSV-tk expressing cells.

Main Results:

• Simultaneous expression of BMP-2 and HSV-tk in TDF cells significantly enhanced in vitro osteogenesis.
• Engineered TDF cells promoted substantial bone formation in critical-size defect models.
• GCV treatment effectively induced apoptosis in the co-expressing TDF cells, demonstrating a controllable suicide gene function.
• The approach showed potential for mitigating risks associated with stem cell therapies, such as tumor formation.

Conclusions:

• Genetically engineered TDF cells co-expressing BMP-2 and HSV-tk offer a safe and effective strategy for bone regeneration.
• The combined gene approach enhances osteo-induction and provides a mechanism for controlling cell proliferation.
• This technique holds significant therapeutic potential for treating bone defects and improving stem cell therapy safety.